Association of N-Linked glycoprotein acetyls and colorectal cancer incidence and mortality

Paulette D. Chandler, Akintunde O. Akinkuolie, Deirdre K. Tobias, Patrick R. Lawler, Chungying Li, M. Vinayaga Moorthy, Lu Wang, Daniel A. Duprez, David R. Jacobs, Robert J. Glynn, James Otvos, Margery A. Connelly, Wendy S. Post, Paul M. Ridker, Jo Ann E Manson, Julie E. Buring, I. Min Lee, Samia Mora

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Background Acute phase proteins highlight the dynamic interaction between inflammation and oncogenesis. GlycA, a novel nuclear magnetic resonance (NMR) inflammatory marker that identifies primarily circulating N-acetyl glycan groups attached to acute phase proteins, may be a future CRC risk biomarker. Methods We examined the association between GlycA and incident CRC and mortality in two prospective cohorts (N = 34,320); Discovery cohort: 27,495 participants from Women's Health Study (WHS); Replication cohort: 6,784 participants from Multi-Ethnic Study of Atherosclerosis (MESA). Multivariable Cox models were adjusted for clinical risk factors and compared GlycA to acute phase proteins (high-sensitivity C-reactive protein [hsCRP], fibrinogen, and soluble intercellular adhesion molecule-1 [sICAM-1]). Results In WHS (median follow-up 19 years, 337 cases, 103 deaths), adjusted HRs (95% CIs) per SD increment of GlycA for CRC incidence and mortality were 1.19 (1.06-1.35; p = 0.004) and 1.24 (1.00-1.55; p = 0.05), respectively. We replicated findings in MESA (median follow-up 11 years, 70 cases, 23 deaths); HRs (95% CIs) per SD of GlycA for CRC incidence and mortality were 1.32 (1.06-1.65; p = 0.01) and 1.54 (1.06-2.23; p = 0.02), respectively, adjusting for age, sex, and race. Pooled analysis, adjusted HR (95% CI) per SD of GlycA for CRC incidence and mortality was 1.26 (1.15-1.39; p = 1 x 10-6 ). Other acute phase proteins (hsCRP, fibrinogen, and sICAM-1) had weaker or no association with CRC incidence, while only fibrinogen and GlycA were associated with CRC mortality. Conclusions The clinical utility of GlycA to personalize CRC therapies or prevention warrants further study.

Original languageEnglish (US)
Article numbere0165615
JournalPloS one
Issue number11
StatePublished - Nov 2016

Bibliographical note

Publisher Copyright:
© 2016 Chandler et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Dive into the research topics of 'Association of N-Linked glycoprotein acetyls and colorectal cancer incidence and mortality'. Together they form a unique fingerprint.

Cite this